Celloid has signed a MOU with EDmicBio, a company specializing in the development of 3D organ-on-a-chip systems using its own in-house 3D bioprinting technology.
This agreement represents a strategic open innovation model between two leading Korean biotech companies, centered around organoids and bioprinting—key technologies driving the future of the bioindustry. The collaboration aims to co-develop liver organoids by integrating liver tissue-derived bioink with automated 3D cell culture technology.
